{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T08:34:47Z","timestamp":1793003687295,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:00:00Z","timestamp":1792800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:00:00Z","timestamp":1792800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2024JDKP0145"],"award-info":[{"award-number":["2024JDKP0145"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chengdu Pharmaceutical Association","award":["Cdyxky8006"],"award-info":[{"award-number":["Cdyxky8006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00228-026-04206-4","type":"journal-article","created":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:28:27Z","timestamp":1792808907000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of GLP-1 receptor agonists for antipsychotic-related overweight and metabolic dysregulation: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"82","author":[{"given":"Lingyan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengbo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,24]]},"reference":[{"key":"4206_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","volume":"9","author":"GBDMD Collaborators","year":"2022","unstructured":"Collaborators GBDMD (2022) Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 9:137\u2013150. https:\/\/doi.org\/10.1016\/S2215-0366(21)00395-3","journal-title":"Lancet Psychiatry"},{"key":"4206_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.eurpsy.2017.02.487","volume":"43","author":"N Jayatilleke","year":"2017","unstructured":"Jayatilleke N, Hayes RD, Dutta R et al (2017) Contributions of specific causes of death to lost life expectancy in severe mental illness. Eur Psychiatry 43:109\u2013115. https:\/\/doi.org\/10.1016\/j.eurpsy.2017.02.487","journal-title":"Eur Psychiatry"},{"key":"4206_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-clinpsy-032813-153657","volume":"10","author":"TM Laursen","year":"2014","unstructured":"Laursen TM, Nordentoft M, Mortensen PB (2014) Excess early mortality in schizophrenia. Annu Rev Clin Psychol 10:425\u2013448. https:\/\/doi.org\/10.1146\/annurev-clinpsy-032813-153657","journal-title":"Annu Rev Clin Psychol"},{"key":"4206_CR4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/wps.20994","volume":"21","author":"CU Correll","year":"2022","unstructured":"Correll CU, Solmi M, Croatto G et al (2022) Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry 21:248\u2013271. https:\/\/doi.org\/10.1002\/wps.20994","journal-title":"World Psychiatry"},{"key":"4206_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.9758\/cpn.2023.21.1.68","volume":"21","author":"M Kim","year":"2023","unstructured":"Kim M, Yang SJ, Kim HH et al (2023) Effects of Dietary Habits on General and Abdominal Obesity in Community-dwelling Patients with Schizophrenia. Clin Psychopharmacol Neurosci 21:68\u201376. https:\/\/doi.org\/10.9758\/cpn.2023.21.1.68","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"4206_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1176\/appi.ajp.20230922","volume":"181","author":"RS Mcintyre","year":"2024","unstructured":"Mcintyre RS, Kwan ATH, Rosenblat JD et al (2024) Psychotropic Drug-Related Weight Gain and Its Treatment. Am J Psychiatry 181:26\u201338. https:\/\/doi.org\/10.1176\/appi.ajp.20230922","journal-title":"Am J Psychiatry"},{"key":"4206_CR7","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1038\/s41380-022-01616-5","volume":"27","author":"SR McWhinney","year":"2022","unstructured":"McWhinney SR, Brosch K, Calhoun VD et al (2022) Obesity and brain structure in schizophrenia - ENIGMA study in 3021 individuals. Mol Psychiatry 27:3731\u20133737. https:\/\/doi.org\/10.1038\/s41380-022-01616-5","journal-title":"Mol Psychiatry"},{"key":"4206_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S2215-0366(15)00115-7","volume":"2","author":"DC Henderson","year":"2015","unstructured":"Henderson DC, Vincenzi B, Andrea NV et al (2015) Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry 2:452\u2013464. https:\/\/doi.org\/10.1016\/S2215-0366(15)00115-7","journal-title":"Lancet Psychiatry"},{"key":"4206_CR9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1089\/cap.2011.0015","volume":"21","author":"L Maayan","year":"2011","unstructured":"Maayan L, Correll CU (2011) Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 21:517\u2013535. https:\/\/doi.org\/10.1089\/cap.2011.0015","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"4206_CR10","doi-asserted-by":"publisher","first-page":"152632","DOI":"10.1016\/j.comppsych.2025.152632","volume":"143","author":"Z Goetz-Kundera","year":"2025","unstructured":"Goetz-Kundera Z, Przekopinska B, Walichniewicz P et al (2025) Comparative effects of pharmacological treatment for weight gain in patients treated with antipsychotics. A systematic review and network meta-analysis. Compr Psychiatry 143:152632. https:\/\/doi.org\/10.1016\/j.comppsych.2025.152632","journal-title":"Compr Psychiatry"},{"key":"4206_CR11","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951\u2013962. https:\/\/doi.org\/10.1016\/S0140-6736(13)60733-3","journal-title":"Lancet"},{"key":"4206_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/wps.20458","volume":"16","author":"D Vancampfort","year":"2017","unstructured":"Vancampfort D, Firth J, Schuch FB et al (2017) Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. World Psychiatry 16:308\u2013315. https:\/\/doi.org\/10.1002\/wps.20458","journal-title":"World Psychiatry"},{"key":"4206_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.psychres.2018.05.055","volume":"267","author":"D Perez-Cruzado","year":"2018","unstructured":"Perez-Cruzado D, Cuesta-Vargas A, Vera-Garcia E et al (2018) Medication and physical activity and physical fitness in severe mental illness. Psychiatry Res 267:19\u201324. https:\/\/doi.org\/10.1016\/j.psychres.2018.05.055","journal-title":"Psychiatry Res"},{"key":"4206_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/0269881115625496","volume":"30","author":"K Mayfield","year":"2016","unstructured":"Mayfield K, Siskind D, Winckel K et al (2016) Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. J Psychopharmacol 30:227\u2013236. https:\/\/doi.org\/10.1177\/0269881115625496","journal-title":"J Psychopharmacol"},{"key":"4206_CR15","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/schbul\/sbu030","volume":"40","author":"Y Mizuno","year":"2014","unstructured":"Mizuno Y, Suzuki T, Nakagawa A et al (2014) Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 40:1385\u20131403. https:\/\/doi.org\/10.1093\/schbul\/sbu030","journal-title":"Schizophr Bull"},{"key":"4206_CR16","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ajcnut.2023.04.017","volume":"118","author":"Y Liu","year":"2023","unstructured":"Liu Y, Ruan B, Jiang H et al (2023) The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. Am J Clin Nutr 118:614\u2013626. https:\/\/doi.org\/10.1016\/j.ajcnut.2023.04.017","journal-title":"Am J Clin Nutr"},{"key":"4206_CR17","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D et al (2024) Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ 384:e076410. https:\/\/doi.org\/10.1136\/bmj-2023-076410","journal-title":"BMJ"},{"key":"4206_CR18","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/acps.13734","volume":"150","author":"M Bak","year":"2024","unstructured":"Bak M, Campforts B, Domen P et al (2024) Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: A systematic review and meta-analysis. Acta Psychiatr Scand 150:516\u2013529. https:\/\/doi.org\/10.1111\/acps.13734","journal-title":"Acta Psychiatr Scand"},{"key":"4206_CR19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/dom.13522","volume":"21","author":"D Siskind","year":"2019","unstructured":"Siskind D, Hahn M, Correll CU et al (2019) Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. Diabetes Obes Metab 21:293\u2013302. https:\/\/doi.org\/10.1111\/dom.13522","journal-title":"Diabetes Obes Metab"},{"key":"4206_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.genhosppsych.2022.07.006","volume":"78","author":"K Lee","year":"2022","unstructured":"Lee K, Abraham S, Cleaver R (2022) A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. Gen Hosp Psychiatry 78:58\u201367. https:\/\/doi.org\/10.1016\/j.genhosppsych.2022.07.006","journal-title":"Gen Hosp Psychiatry"},{"key":"4206_CR21","doi-asserted-by":"publisher","first-page":"1153648","DOI":"10.3389\/fpsyt.2023.1153648","volume":"14","author":"A Khaity","year":"2023","unstructured":"Khaity A, Mostafa Al-Dardery N, Albakri K et al (2023) Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis. Front Psychiatry 14:1153648. https:\/\/doi.org\/10.3389\/fpsyt.2023.1153648","journal-title":"Front Psychiatry"},{"key":"4206_CR22","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1177\/10600280251414107","volume":"60","author":"S Pascale","year":"2026","unstructured":"Pascale S, Reinert JP (2026) Efficacy and Safety of GLP-1 Receptor Agonists for the Management of Antipsychotic-Induced Weight Gain. Ann Pharmacother 60:991\u20131001. https:\/\/doi.org\/10.1177\/10600280251414107","journal-title":"Ann Pharmacother"},{"key":"4206_CR23","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1177\/00912174261422822","volume":"61","author":"M Srisurapanont","year":"2026","unstructured":"Srisurapanont M, Suttajit S, Likhitsathian S et al (2026) Glucagon-like peptide-1 receptor agonists in individuals with severe mental illness: A systematic review and meta-analysis of randomized controlled trials. Int J Psychiatry Med 61:312\u2013328. https:\/\/doi.org\/10.1177\/00912174261422822","journal-title":"Int J Psychiatry Med"},{"key":"4206_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/JCP.0000000000001803","volume":"44","author":"SL McElroy","year":"2024","unstructured":"McElroy SL, Guerdjikova AI, Blom TJ et al (2024) Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder. J Clin Psychopharmacol 44:89\u201395. https:\/\/doi.org\/10.1097\/JCP.0000000000001803","journal-title":"J Clin Psychopharmacol"},{"key":"4206_CR25","doi-asserted-by":"publisher","unstructured":"Lee S, Kim MG, Trott M et al (2026) Effects of glucagon-like peptide-1 receptor agonists on anthropometric and adiposity measures in patients with antipsychotic-induced weight gain: A systematic review and meta-analysis. J Psychopharmacol 2698811261456190. https:\/\/doi.org\/10.1177\/02698811261456190","DOI":"10.1177\/02698811261456190"},{"key":"4206_CR26","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1001\/jamapsychiatry.2026.1814","volume":"83","author":"N Stogios","year":"2026","unstructured":"Stogios N, Agarwal SM, Maksyutynska K et al (2026) Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis. JAMA Psychiatry 83:912\u2013920. https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.1814","journal-title":"JAMA Psychiatry"},{"key":"4206_CR27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","volume":"82","author":"ACS Pierret","year":"2025","unstructured":"Pierret ACS, Mizuno Y, Saunders P et al (2025) Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis. JAMA Psychiatry 82:643\u2013653. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0679","journal-title":"JAMA Psychiatry"},{"key":"4206_CR28","doi-asserted-by":"publisher","first-page":"1330936","DOI":"10.3389\/fendo.2024.1330936","volume":"15","author":"W Chen","year":"2024","unstructured":"Chen W, Cai P, Zou W et al (2024) Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database. Front Endocrinol (Lausanne) 15:1330936. https:\/\/doi.org\/10.3389\/fendo.2024.1330936","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4206_CR29","unstructured":"European Medicines Agency (2024) PRAC finds no link between suicidal thoughts and thoughts of self-harm and GLP-1 receptor agonists. European Medicines Agency, Amsterdam. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024. Accessed 20 September 2026"},{"key":"4206_CR30","volume-title":"FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications","author":"U.S. Food, Drug Administration","year":"2026","unstructured":"U.S. Food, Drug Administration (2026) FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. U.S. Food and Drug Administration, Silver Spring (MD). https:\/\/www.fda.gov\/drugs\/drug-safety-communications\/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp"},{"key":"4206_CR31","doi-asserted-by":"publisher","unstructured":"Ebrahimi P, Batlle JC, Ayati A et al (2025) Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity: A Systematic Review and Meta-Analysis. JAMA Psychiatry 82:888\u2013895. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0091 Accessed 20 September 2026","DOI":"10.1001\/jamapsychiatry.2025.0091"},{"key":"4206_CR32","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"4206_CR33","volume-title":"Empirical assessment of within-arm correlation imputation in trials of continuous outcomes. AHRQ Methods for Effective Health Care","author":"EM Balk","year":"2012","unstructured":"Balk EM, Earley A, Patel K et al (2012) Empirical assessment of within-arm correlation imputation in trials of continuous outcomes. AHRQ Methods for Effective Health Care. Agency for Healthcare Research and Quality, Rockville (MD)"},{"key":"4206_CR34","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/dom.13167","volume":"20","author":"DJ Siskind","year":"2018","unstructured":"Siskind DJ, Russell AW, Gamble C et al (2018) Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX). Diabetes Obes Metab 20:1050\u20131055. https:\/\/doi.org\/10.1111\/dom.13167","journal-title":"Diabetes Obes Metab"},{"key":"4206_CR35","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1001\/jamapsychiatry.2025.2332","volume":"82","author":"AA Ganeshalingam","year":"2025","unstructured":"Ganeshalingam AA, Uhrenholt N, Arnfred S et al (2025) Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial. JAMA Psychiatry 82:1065\u20131074. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.2332","journal-title":"JAMA Psychiatry"},{"key":"4206_CR36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S2215-0366(25)00129-4","volume":"12","author":"D Siskind","year":"2025","unstructured":"Siskind D, Baker A, Arnautovska U et al (2025) Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia. Lancet Psychiatry 12:493\u2013503. https:\/\/doi.org\/10.1016\/S2215-0366(25)00129-4","journal-title":"Lancet Psychiatry"},{"key":"4206_CR37","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1001\/jamapsychiatry.2025.3639","volume":"83","author":"MR Sass","year":"2026","unstructured":"Sass MR, Klausen MK, Schwarz CR et al (2026) Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial. JAMA Psychiatry 83:128\u2013138. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.3639","journal-title":"JAMA Psychiatry"},{"key":"4206_CR38","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/dom.14334","volume":"23","author":"CA Whicher","year":"2021","unstructured":"Whicher CA, Price HC, Phiri P et al (2021) The use of liraglutide 3.0\u00a0mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 23:1262\u20131271. https:\/\/doi.org\/10.1111\/dom.14334","journal-title":"Diabetes Obes Metab"},{"key":"4206_CR39","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","volume":"74","author":"JR Larsen","year":"2017","unstructured":"Larsen JR, Vedtofte L, Jakobsen MSL et al (2017) Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial. JAMA Psychiatry 74:719\u2013728. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.1220","journal-title":"JAMA Psychiatry"},{"key":"4206_CR40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/dom.12795","volume":"19","author":"PL Ishoy","year":"2017","unstructured":"Ishoy PL, Knop FK, Broberg BV et al (2017) Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. Diabetes Obes Metab 19:162\u2013171. https:\/\/doi.org\/10.1111\/dom.12795","journal-title":"Diabetes Obes Metab"},{"key":"4206_CR41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jad.2025.04.046","volume":"382","author":"LR Patino","year":"2025","unstructured":"Patino LR, Strawn JR, Adler CM et al (2025) A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults. J Affect Disord 382:116\u2013122. https:\/\/doi.org\/10.1016\/j.jad.2025.04.046","journal-title":"J Affect Disord"},{"key":"4206_CR42","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"4206_CR43","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.psyneuen.2004.05.008","volume":"30","author":"M Murashita","year":"2005","unstructured":"Murashita M, Kusumi I, Inoue T et al (2005) Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 30:106\u2013110. https:\/\/doi.org\/10.1016\/j.psyneuen.2004.05.008","journal-title":"Psychoneuroendocrinology"},{"key":"4206_CR44","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/j.1399-5618.2008.00625.x","volume":"10","author":"CU Correll","year":"2008","unstructured":"Correll CU, Frederickson AM, Kane JM et al (2008) Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 10:788\u2013797. https:\/\/doi.org\/10.1111\/j.1399-5618.2008.00625.x","journal-title":"Bipolar Disord"},{"key":"4206_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1192\/bjb.2023.29","volume":"48","author":"K Lee","year":"2024","unstructured":"Lee K, Akinola A, Abraham S (2024) Antipsychotic-induced weight gain: exploring the role of psychiatrists in managing patients\u2019 physical health - challenges, current options and direction for future care. BJPsych Bull 48:24\u201329. https:\/\/doi.org\/10.1192\/bjb.2023.29","journal-title":"BJPsych Bull"},{"key":"4206_CR46","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s44446-025-00038-y","volume":"33","author":"AG Alharbi","year":"2025","unstructured":"Alharbi AG (2025) GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity. Saudi Pharm J 33:34. https:\/\/doi.org\/10.1007\/s44446-025-00038-y","journal-title":"Saudi Pharm J"},{"key":"4206_CR47","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M et al (2021) Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA 325:1414\u20131425. https:\/\/doi.org\/10.1001\/jama.2021.3224","journal-title":"JAMA"},{"key":"4206_CR48","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW Le Roux","year":"2017","unstructured":"Le Roux CW, Astrup A, Fujioka K et al (2017) 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389:1399\u20131409. https:\/\/doi.org\/10.1016\/S0140-6736(17)30069-7","journal-title":"Lancet"},{"key":"4206_CR49","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.2337\/dc16-2368","volume":"40","author":"M Abdul-Ghani","year":"2017","unstructured":"Abdul-Ghani M, Defronzo RA (2017) Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. Diabetes Care 40:1121\u20131127. https:\/\/doi.org\/10.2337\/dc16-2368","journal-title":"Diabetes Care"},{"key":"4206_CR50","doi-asserted-by":"publisher","first-page":"i5953","DOI":"10.1136\/bmj.i5953","volume":"355","author":"Y Huang","year":"2016","unstructured":"Huang Y, Cai X, Mai W et al (2016) Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ 355:i5953. https:\/\/doi.org\/10.1136\/bmj.i5953","journal-title":"BMJ"},{"key":"4206_CR51","doi-asserted-by":"publisher","first-page":"24103","DOI":"10.1038\/s41598-025-09807-0","volume":"15","author":"X Ren","year":"2025","unstructured":"Ren X, Hua H, Wu Y et al (2025) Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis. Sci Rep 15:24103. https:\/\/doi.org\/10.1038\/s41598-025-09807-0","journal-title":"Sci Rep"},{"key":"4206_CR52","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1038\/s41366-025-01859-6","volume":"49","author":"A Ismaiel","year":"2025","unstructured":"Ismaiel A, Scarlata GGM, Boitos I et al (2025) Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis. Int J Obes (Lond) 49:1946\u20131957. https:\/\/doi.org\/10.1038\/s41366-025-01859-6","journal-title":"Int J Obes (Lond)"},{"key":"4206_CR53","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/s42255-026-01567-z","volume":"8","author":"T Zhang","year":"2026","unstructured":"Zhang T, He P, Ji Y et al (2026) Association of GLP-1RA discontinuation and risk of depressive and anxiety disorders in people with type 2 diabetes: a cohort study. Nat Metab 8:1489\u20131494. https:\/\/doi.org\/10.1038\/s42255-026-01567-z","journal-title":"Nat Metab"},{"key":"4206_CR54","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 377:1228\u20131239. https:\/\/doi.org\/10.1056\/NEJMoa1612917","journal-title":"N Engl J Med"},{"key":"4206_CR55","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375:311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"4206_CR56","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 389:2221\u20132232. https:\/\/doi.org\/10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"4206_CR57","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.rcpeng.2022.06.006","volume":"53","author":"O Ribero","year":"2024","unstructured":"Ribero O, Castilloux AM, Agudelo LM et al (2024) Effectiveness of Paliperidone Palmitate on Treatment Adherence and Relapse in the Adult Schizophrenia Population: A One-Year Mirror-Image Study in a Colombian Mental Health Care Facility. Rev Colomb Psiquiatr (Engl Ed) 53:426\u2013434. https:\/\/doi.org\/10.1016\/j.rcpeng.2022.06.006","journal-title":"Rev Colomb Psiquiatr (Engl Ed)"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04206-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04206-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04206-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T08:05:47Z","timestamp":1793001947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04206-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,24]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["4206"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04206-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,24]]},"assertion":[{"value":"29 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Given that this systematic review and meta-analysis did not utilize primary data from individual participants, formal ethical approval was not sought. The protocol has been registered with PROSPERO (CRD420261290294).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have reviewed and approved the final version of this manuscript and consent to its submission and publication in European Journal of Clinical Pharmacology.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"278"}}